Author

Lauren R. L. Lohmer

Observed names: L. R. L. Lohmer, Lauren L. R. Lohmer, Lauren Lohmer, Lauren R.L. Lohmer

Institution: Indivior (United States)

Observed institution: Indivior (United States)

ORCID: 0000-0001-9716-4711

Observed ORCID: 0000-0001-9716-4711

OpenAlex ID: A5000141938

The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19

2020 · Virginia D. Schmith, Jie (Jessie) Zhou, et al. · Clinical Pharmacology & Therapeutics · 261

PDF

A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects

2020 · Michael J. Fossler, Virginia Schmith, et al. · CNS Drugs · 32

PDF

A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation

2021 · Jie Zhou, Laura Curd, et al. · Clinical and Translational Science · 26

PDF

A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors

2022 · Olivier Schueller, Ashley Willson, et al. · Clinical Pharmacology in Drug Development · 17

Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]‐Belumosudil in Healthy Men: A Phase 1, Open‐Label, 2‐Part Study

2022 · Olivier Schueller, Ed Skucas, et al. · Clinical Pharmacology in Drug Development · 12

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder

2019 · Virginia D. Schmith, Laura Curd, et al. · Clinical Pharmacology & Therapeutics · 12

PDF

Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects

2022 · Olivier Schueller, John McDermott, et al. · Clinical Pharmacology in Drug Development · 10

Two‐Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants

2024 · Olivier Schueller, Galit Regev, et al. · Clinical Pharmacology in Drug Development · 6

PDF

A Phase 1 Thorough QT/QTc Study of Therapeutic and Supratherapeutic Doses of Belumosudil in Healthy Subjects

2022 · Olivier Schueller, Lauren Lohmer, et al. · Clinical Pharmacology in Drug Development · 5

Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model

2022 · Frank Z. Stanczyk, David F. Archer, et al. · PLoS ONE · 4

PDF

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

2025 · Olivier Schueller, Lauren Lohmer, et al. · The Journal of Clinical Pharmacology · 2

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications

2026 · Virginia D. Schmith, Danielle Graden, et al. · Clinical and Translational Science · 1

PDF

Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment

2025 · Olivier Schueller, Virginie Esposito, et al. · Clinical and Translational Science · 1

PDF

Optimal buprenorphine exposure to treat patients with opioid use disorder in the era of fentanyl and polysubstance use

2026 · L. R. L. Lohmer, M. K. Greenwald, et al. · Frontiers in Pharmacology

PDF

Exposure-Response Analyses for Monthly Buprenorphine Extended-Release (BUP-XR) in Patients with Opioid Use Disorder and Frequent Fentanyl Use

2026 · Lauren Lohmer, Mark Greenwald, et al.

PDF

Works count: 15

Citation count: 389

H-index: 7

I10-index: 7